We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
-2.63%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.26B
AUM Growth
-$529M
(-19%)
Cap. Flow
-$492M
Cap. Flow
% of AUM
-21.74%
Top 10 Holdings %
Top 10 Hldgs %
34.63%
Holding
101
New
12
Increased
22
Reduced
23
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$36.9M |
| 2 |
DexCom
DXCM
|
+$32.3M |
| 3 |
BLUE
bluebird bio
BLUE
|
+$24.8M |
| 4 |
Acadia Healthcare
ACHC
|
+$24.2M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$23.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$46.8M |
| 2 |
Biogen
BIIB
|
+$43.1M |
| 3 |
AstraZeneca
AZN
|
+$39.1M |
| 4 |
Axsome Therapeutics
AXSM
|
+$32M |
| 5 |
Agilent Technologies
A
|
+$27.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Agilent Technologies
A
$40.6B
| – | – |
-183,504
| Closed | -$27.5M |
|
77
CALL
AbbVie
ABBV
$432B
| – | – |
-100,000
| Closed | -$16.2M |
|
|
78
CALL
Axsome Therapeutics
AXSM
$10.8B
| – | – |
-299,000
| Closed | -$23.1M |
|
|
79
AstraZeneca
AZN
$250B
| – | – |
-288,400
| Closed | -$39.1M |
|
80
Biohaven
BHVN
$2.2B
| – | – |
-10,988
| Closed | -$153K |
|
|
81
Biogen
BIIB
$30.2B
| – | – |
-155,659
| Closed | -$43.1M |
|
82
CALL
BioMarin Pharmaceuticals
BMRN
$12.3B
| – | – |
-243,000
| Closed | -$25.1M |
|
|
BPMC
83
DELISTED
Blueprint Medicines
BPMC
| – | – |
-130,366
| Closed | -$5.71M |
|
|
84
Cigna
CI
$74.5B
| – | – |
-141,300
| Closed | -$46.8M |
|
85
Charles River Laboratories
CRL
$12.7B
| – | – |
-72,820
| Closed | -$15.9M |
|
|
ITOS
86
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-70,922
| Closed | -$1.39M |
|
87
PUT
Jazz Pharmaceuticals
JAZZ
$16.6B
| – | – |
-128,500
| Closed | -$20.5M |
|
88
Johnson & Johnson
JNJ
$619B
| – | – |
-137,746
| Closed | -$24.3M |
|
|
89
PUT
Johnson & Johnson
JNJ
$619B
| – | – |
-450,000
| Closed | -$79.5M |
|
90
CALL
Labcorp
LH
$25.8B
| – | – |
-261,900
| Closed | -$53M |
|
|
91
Labcorp
LH
$25.8B
| – | – |
-15,785
| Closed | -$3.19M |
|
92
Pulmonx
LUNG
$87.6M
| – | – |
-1,455,770
| Closed | -$12.3M |
|
93
CALL
Merck
MRK
$313B
| – | – |
-871,500
| Closed | -$96.7M |
|
94
CALL
Penumbra
PEN
$12.8B
| – | – |
-237,500
| Closed | -$52.8M |
|
95
CALL
Prothena Corp
PRTA
$458M
| – | – |
-152,300
| Closed | -$9.18M |
|
96
CALL
UnitedHealth
UNH
$371B
| – | – |
-69,600
| Closed | -$36.9M |
|
|
JNCE
97
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| – | – |
-345,926
| Closed | -$384K |
|
|
OSH
98
DELISTED
Oak Street Health, Inc.
OSH
| – | – |
-565,239
| Closed | -$12.2M |
|
Similar funds
DAM
MAM
DAM
KCM
MIA
YL
SL
PWA
PFM Health Sciences's Q1 2023 Portfolio in Review
As of Q1 2023, PFM Health Sciences held 101 positions worth $2.26B, down 19% from $2.79B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
PFM Health Sciences withdrew a net $492M in Q1 2023, closing 23 positions and reducing 23 holdings. Its most notable exit was Cigna, an estimated $46.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 81% a quarter earlier.
Against the trend, PFM Health Sciences opened a new position in Becton Dickinson worth $37.4M.
- PFM Health Sciences's largest Q1 2023 buy was Becton Dickinson: 151,013 shares worth $37.4M.
- PFM Health Sciences added most to DexCom in Q1 2023, an estimated $32.3M increase.
- PFM Health Sciences's biggest Q1 2023 reduction was Axsome Therapeutics, cutting an estimated $32M.
- PFM Health Sciences fully exited Cigna in Q1 2023, selling an estimated $46.8M.
- PFM Health Sciences's ten largest holdings make up 35% of its $2.26B portfolio in Q1 2023.
- PFM Health Sciences opened 12 new positions and closed 23 in Q1 2023.
- PFM Health Sciences's portfolio value fell 19% quarter-over-quarter to $2.26B.
Based on PFM Health Sciences's 13F filing for Q1 2023, filed 15 May 2023.